I. Overview of Clinical Trial Endpoints for Common Ophthalmic DiseasesThe appropriate selection of endpoints in ophthalmic drug clinical trials directly determines the scientific validity of a study a...
IntroductionCell and Gene Therapy (CGT) is transforming the treatment landscape for difficult-to-treat diseases, particularly cancers and rare disorders. However, the path from lab to market remains s...
As Cell and Gene Therapy (CGT) products transition from the laboratory to the clinic, the design of the clinical trial protocol is not only the starting point for scientific exploration but also the c...
Executive SummaryGCP ClinPlus established a transformative decade-long partnership with a US biotech company, delivering comprehensive biostatistics and SAS programming capabilities that significantly...
In the fast-paced field of oncology drug development, the addition of a new indication often presents complex regulatory, operational, and scientific challenges. In late 2024, ...
GCP ClinPlus Enhances Trial Delivery for a U.S.-Based Ophthalmology SponsorThe ChallengeDuring a critical phase of multiple ophthalmology trials, the sponsor faced fluctuating programming workloads ...
